CPL304110 is an Orally Active and Selective FGFR(1-3) Inhibitor
Over the last decade, the FGFRs family has become an attractive validated therapeutic target notably in cancer. It consists of four members (FGFR1 to FGFR4) which are structurally related cell surface RTKs. This FGF-FGFR axis participates in key biological processes that play significant roles in cell functions such as...
BAY1082439 is an Orally Active and Selective Balanced PI3Kα/β/δ Inhibitor
Prostate cancer is among the most common malignancy in males. Among the various PI3K isoforms, PTEN-loss-induced prostate cancer in the genetically engineered Pten conditional knockout mouse model predominantly activates the PI3Kβ subunit. However, selective inhibition of PI3Kβ shows no significant anti-tumor efficacy in PTEN-null prostate cancer cell lines. It...
LCH-7749944 is a Potent PAK4 Inhibitor and Induces Apoptosis
P21-activated kinase 4 (PAK4) is a serine/threonine protein kinase and has related to the regulation of cytoskeleton recombine, cell proliferation, gene transcription, carcinogenic transformation, cell invasion. Moreover, PAK4 overexpression, mutations, genetic amplification were detected in a variety of human tumors, making it a potential therapeutic target. Specifically, The p21-activated kinases...
SU16f is a Selective PDGFRβ Inhibitor for Gastric Cancer Therapy
Mesenchymal stem cells (MSCs) are multipotent progenitor cells that play a critical role in tissue regeneration. MSCs play an important role in matrix remodeling, fibroblast activation, angiogenesis, and immunomodulation. MSCs are an integral part of fibrovascular networks that form in developing tissues and tumors. A multitude of soluble proteins...